Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209127
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The AETHERA trial demonstrated that brentuximab vedotin (BV) consolidation after autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL) at high risk of relapse/progression increases progression-free survival (PFS). Patients previously exposed to BV were excluded from that trial. However, BV alone or in combination with chemotherapy is frequently used as front-line treatment and/or pre-ASCT salvage therapy. We analyzed data from 156 patients with high-risk HL who underwent ASCT with (BV-CON, n?=?62) or without (non-BV, n?=?94) BV consolidation. Fifty-seven patients received BV-based salvage regimens before ASCT. The 3-year overall survival and PFS for all patients were 91.6% and 70.0%, respectively. Multivariate analysis showed that BV-CON was associated with better PFS (HR 0.39, p?=?0.01), whereas positive PET at transplant leaded to worse PFS (HR 2.71, p?=?0.001). BV-CON improved PFS in PET-positive patients (72.2% vs. 43.0%, p?=?0.05), with a beneficial trend observed in PET negative (88.8% vs. 75.2%, p?=?0.09). BV-CON patients with or without BV exposure pre-ASCT had a significantly better PFS than non-BV with or without BV pretransplant treatment (HR 0.36, p?=?0.004). The efficacy of real-life BV consolidation therapy was similar to that in the AETHERA trial. This therapeutic strategy improves survival independently of BV exposure prior to ASCT.© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Matèries
Matèries (anglès)
Citació
Citació
MARTINEZ, Carmen, HARO, Manuel espeso de, ROMERO, Samuel, GUTIERREZ, Antonio, DOMINGO DOMÈNECH, Eva, GONZÁLEZ RODRÍGUEZ, Ana p., ZEBERIO, Izaskun, MARTÍNEZ BADAS, María paz, RODRÍGUEZ IZQUIERDO, Antonia, CARPIO, Cecilia, BASTOS OREIRO, Mariana, HERNANDEZ RIVAS, Jose angel, VALLANSOT, Rolando, KELLEHER, Nicholas, DÍAZ GÁLVEZ, Francisco j., TORRADO, Tamara, PEREIRA, Arturo, GARCIA SANZ, Ramon. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. _Annals Of Hematology_. 2023. Vol. 102, núm. 2, pàgs. 429-437. [consulta: 21 de gener de 2026]. ISSN: 1432-0584. [Disponible a: https://hdl.handle.net/2445/209127]